It has been established that CD3E is overexpressed in patients with T-cell ALL (50), and that patients with this condition and that a remission of the disease can be obtained with an anti-CD3E recombinant immunotoxin (51). Here, CD3E is linked to T-cell acute lymphoblastic leukemia.